|
|
Article: National Institute on Aging Selects SRI International to Qualify Alzheimers Drug Candidates for Clinical Studies.
- Article from:
- Business Wire
- Article date:
- November 15, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MENLO PARK, Calif. -- Five-Year Contract Totaling $6.3M to Conduct Preclinical Safety Assessments
Under a five-year contract, totaling approximately $6.3 million, the National Institute on Aging (NIA) has selected SRI International to evaluate the preclinical safety and pharmacology of potential therapeutics for treatment of Alzheimers disease and other diseases associated with aging. NIA will use SRI's preclinical studies to support Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) to perform clinical studies. The primary objective of the program is to perform safety and pharmacokinetics testing of therapeutic agents.
...